LOXO ONCOLOGY INC. overview

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders PR Newswire NEW YORK, Jan. 8, 2019 NEW YORK , Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. ("LOXO" or the "Company") (NASDAQ: LOXO) in connection with the proposed acquisition of the Company by Eli Lilly Company (NYSE: LLY) ("LLY"). Under the terms of the acquisition...

NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Loxo Oncology Inc (NASDAQ: LOXO ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:00 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22097 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor Network...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Loxo Oncology, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire NEW YORK, May 10, 2017 NEW YORK , May 10, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Loxo Oncology, Inc. (NASDAQ: LOXO). If you are a shareholder of Loxo...

STAMFORD, Conn., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the closing of its previously announced underwritten public offering of 4,450,500 shares of common stock at a public offering price of $31.00 per share, which included the exercise in full by the underwriters of their option to purchase 580,500 additional shares of...

STAMFORD, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 3,870,000 shares of common stock at a public offering price of $31.00 per share. Gross proceeds to Loxo Oncology from this offering are expected to be approximately $120 million. Loxo Oncology intends to use the net...

STAMFORD, Conn., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced today that it intends to offer shares of its common stock in an underwritten public offering. Loxo Oncology also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering at the public offering price...

– Larotrectinib Approximately 85% Enrolled to Goal; Completion of Enrollment for Primary Efficacy Analysis Expected Early 2017 – – NDA Submission for Larotrectinib Expected Late 2017 or Early 2018 – – Company to Host Investor Conference Call and Webcast Today at 8:00 a.m. EST – STAMFORD, Conn., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined...

– Six of Seven TRK Fusion Patients Achieve Confirmed RECIST Partial Responses and All Remain in Response – – All TRK Fusion Patients Remain on Study With Median Follow-Up of 15 Cycles – – Company to Host Investor Conference Call and Webcast on Monday, December 19, 2016 at 8:00 a.m. EST – STAMFORD, Conn., Dec. 18, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...